📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-07 13:29
0 analysed today
FollowTelegram
0
Today
151,859
All-time analysed
43,535
Positive
6,743
Negative
92,744
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
3 announcements match the current filters (relevance ≥ 5).
Vivanza Biosciences Approves Q1 FY27 Results; TTM Revenue at Rs 116 Cr
Vivanza Biosciences approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company operates with a very small market capitalization of Rs 8 Cr and has shown significant revenue volatility, with the previous quarter (Mar 2026) seeing a sharp drop to Rs 6.36 Cr from Rs 45.25 Cr in Dec 2025. The board also confirmed director qualifications and independence as per statutory requirements. Investors should note the high debt-to-equity ratio of 2.50 and low promoter holding of 20.02%.
Confidence: MEDIUM
What changedThe board has officially approved and recorded the financial performance for the first quarter of the 2026-27 fiscal year.
Why it mattersFor a micro-cap company with high debt and low promoter skin-in-the-game, quarterly results are critical to monitor liquidity and the ability to service its Rs 10 Cr debt.
TTM Revenue: Rs 116 CrMarket Cap: Rs 8 CrDebt-to-Equity Ratio: 2.50Promoter Holding: 20.02%Quarter Ended: 30th June, 2026
📅 Short termThe stock may remain range-bound given the micro-cap nature and the lack of immediate growth catalysts in the procedural announcement.
📈 Long termThe company's high leverage (D/E 2.50) and low operating margins (0.6%) suggest a high-risk profile unless consistent profitability is established.
⚠ Risk flags
- High debt-to-equity ratio (2.50)
- Low promoter holding (20.02%)
- Extreme quarterly revenue volatility
- Micro-cap liquidity risks
Key Highlights
Board approved unaudited financial results for the quarter ended June 30, 2026
The board meeting was brief, lasting 15 minutes from 12:45 PM to 1:00 PM
Company maintains a high debt-to-equity ratio of 2.50 based on latest financial context
TTM revenue stands at Rs 116 Cr, which is significantly higher than its Rs 8 Cr market cap
Promoter holding remains stagnant at 20.02% as of the latest reporting period
👀 What to Watch
Investors should examine the detailed P&L statement (Annexure A) to see if revenue has recovered from the low of Rs 6.36 Cr reported in the March 2026 quarter.
Vivanza Biosciences Approves Q1 FY27 Financial Results
Vivanza Biosciences approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, in a board meeting held on August 7, 2026. The company operates with a very small market cap of ‑8 Cr and a high debt-to-equity ratio of 2.50, making quarterly performance critical for solvency. While TTM revenue is significant at ‑116 Cr, the company has struggled with razor-thin operating margins of 0.6% and reported a loss of ‑0.45 Cr in the preceding March 2026 quarter. Investors should focus on whether the company has stabilized its bottom line in this new reporting period.
Confidence: HIGH
What changedThe company has completed its board-level review and approval of financial performance for the first quarter of the 2026-27 fiscal year.
Why it mattersFor a micro-cap company with high leverage (Debt of ‑10 Cr vs Net Worth of ‑4 Cr), these results are essential to determine if the business can generate enough cash flow to service its debt.
Market Cap: ‑8 CrTTM Revenue: ‑116 CrDebt-to-Equity Ratio: 2.50TTM Operating Profit Margin: 0.6%Promoter Holding: 20.02%
📅 Short termThe stock price may remain volatile as the market digests the specific profit/loss figures from the Q1 results, especially given the previous quarter's loss.
📈 Long termLimited structural significance unless the company can significantly improve its margins and reduce its high debt burden relative to its net worth.
⚠ Risk flags
- High Debt-to-Equity ratio (2.50)
- Low operating margins (0.6%)
- Low promoter holding (20.02%)
- Negative net worth relative to debt
Key Highlights
Board approved unaudited financial results for the quarter ended June 30, 2026
Company maintains a high Debt-to-Equity ratio of 2.50 as per latest financial context
TTM revenue stands at ‑116 Cr, which is 14.5x its current market capitalization of ‑8 Cr
Promoter holding remains relatively low at 20.02%
The meeting concluded within 15 minutes, starting at 12:45 P.M. and ending at 13:00 P.M.
👀 What to Watch
Review the detailed P&L in the full results filing to check for any improvement in the 0.6% operating margin and to see if the company has recovered from the ‑0.45 Cr loss reported in the previous quarter.
Vivanza Biosciences Approves Q1 FY27 Unaudited Financial Results
Vivanza Biosciences approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, in a board meeting held on August 7, 2026. The company operates with a significant TTM revenue of ₹116 Cr relative to its small market capitalization of ₹8 Cr, but faces challenges with a thin operating margin of 0.6%. Investors should note the high debt-to-equity ratio of 2.50 and a relatively low promoter holding of 20.02%. The meeting was brief, concluding within 15 minutes.
Confidence: HIGH
What changedThe company has formally approved and released its financial performance data for the first quarter of the 2026-27 fiscal year.
Why it mattersFor a micro-cap company with high leverage (D/E 2.50) and low margins, quarterly results are the primary indicator of its ability to service debt and maintain operations.
Market Cap: ₹8 CrTTM Revenue: ₹116 CrDebt-to-Equity Ratio: 2.50Operating Profit Margin: 0.6%Promoter Holding: 20.02%
📅 Short termThe stock price may see volatility depending on the specific net profit figures disclosed in the full results, given the company's small market cap.
📈 Long termLimited structural significance unless the company demonstrates a clear path to margin expansion and debt reduction over multiple quarters.
⚠ Risk flags
- High Debt-to-Equity ratio (2.50)
- Low promoter holding (20.02%)
- Extremely thin operating margins (0.6%)
- Micro-cap liquidity risk
Key Highlights
Approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026
Board meeting duration was 15 minutes, starting at 12:45 P.M. and concluding at 13:00 P.M.
Company maintains a high Debt-to-Equity ratio of 2.50 as per latest financial context
TTM Revenue of ₹116 Cr is significantly higher than the current Market Cap of ₹8 Cr
Promoter holding remains stagnant at 20.02% as of the last reporting period
👀 What to Watch
Investors should examine the detailed quarterly P&L to see if the company has recovered from the ₹0.45 Cr net loss reported in the March 2026 quarter and if operating margins have improved from the current 0.6%.
